Literature DB >> 23055880

Community-Associated Methicillin-Resistant Staphylococcus aureus in the Pediatric Population.

Carrie W Nemerovski1, Kristin C Klein.   

Abstract

PURPOSE: To review the epidemiology and prevalence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), define the differences between community-acquired and hospital-acquired strains, highlight the advantages and disadvantages of antibiotics commonly used to treat infections caused by this pathogen, and identify strategies to limit the spread of this organism and prevent future outbreaks. DATA: Literature was accessed through MEDLINE using the search terms community-acquired methicillin-resistant Staphylococcus aureus, community-associated methicillin-resistant Staphylococcus aureus, CA-MRSA, pediatrics, and children. Articles evaluated were published in the English language and limited to human studies. References of literature identified by initial search techniques were reviewed for additional relevant articles. DATA SYNTHESIS: Community-associated methicillin-resistant Staphylococcus aureus has become a prominent pathogen in pediatric patients in the last ten years. Its increasing prevalence has been reported throughout the United States, and it is the cause of over one half of all skin and soft tissue infections seen in many hospitals and emergency departments. The risk factors for infection with this pathogen differ from those associated with hospital-acquired strains. Mild to moderate infections can generally be treated with oral antibiotics, while more serious infections may require parenteral therapy. Sulfamethoxazole/trimethoprim and clindamycin are the preferred oral agents due to their efficacy, tolerability, well established side effect profiles, and cost. Vancomycin is the standard of care for parenteral therapy, although clindamycin is an acceptable parenteral alternative. More costly agents such as linezolid, daptomycin, and quinupristin/dalfopristin should be reserved for patients with severe infections, multiple allergies, or in strains with unusual resistance patterns. The best way to prevent and control outbreaks is to maintain standard infection control procedures including excellent hand hygiene.
CONCLUSIONS: CA-MRSA is a serious and frequently seen pathogen. Proper antibiotic selection that takes into account patient factors, disease severity, ease of administration, and cost is necessary to maximize favorable patient outcomes.

Entities:  

Keywords:  CA-MRSA; children; community-acquired methicillin-resistant Staphylococcus aureus; community-associated methicillin-resistant Staphylococcus aureus; pediatrics

Year:  2008        PMID: 23055880      PMCID: PMC3461986          DOI: 10.5863/1551-6776-13.4.212

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  62 in total

1.  Cutaneous community-associated methicillin-resistant staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments.

Authors:  Molly B Hasty; Ann Klasner; Sean Kness; T Kent Denmark; Don Ellis; Martin I Herman; Lance Brown
Journal:  Acad Emerg Med       Date:  2006-11-21       Impact factor: 3.451

2.  Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.

Authors:  John D Szumowski; Daniel E Cohen; Fumihide Kanaya; Kenneth H Mayer
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 3.  Community-acquired methicillin-resistant Staphylococcus aureus causes severe disseminated infection and deep venous thrombosis in children: literature review and recommendations for management.

Authors:  Clare Nourse; Mike Starr; Wendy Munckhof
Journal:  J Paediatr Child Health       Date:  2007-06-29       Impact factor: 1.954

4.  Emergence of community-acquired methicillin-resistant Staphylococcus aureus soft tissue infections.

Authors:  Max Olesevich; Alfred Kennedy
Journal:  J Pediatr Surg       Date:  2007-05       Impact factor: 2.545

5.  A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection.

Authors:  Loren G Miller; Clifford Quan; Anthony Shay; Katayoun Mostafaie; Kiran Bharadwa; Nelly Tan; Kelli Matayoshi; Jason Cronin; Jennifer Tan; Grace Tagudar; Arnold S Bayer
Journal:  Clin Infect Dis       Date:  2007-01-12       Impact factor: 9.079

Review 6.  Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin.

Authors:  Susan Boyle-Vavra; Robert S Daum
Journal:  Lab Invest       Date:  2006-12-04       Impact factor: 5.662

7.  Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis.

Authors:  Ronda L Akins; Mark R Haase; Eric N Levy
Journal:  Pharmacotherapy       Date:  2006-05       Impact factor: 4.705

Review 8.  Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.

Authors:  G J Noel
Journal:  Clin Microbiol Infect       Date:  2007-06       Impact factor: 8.067

Review 9.  The molecular evolution of methicillin-resistant Staphylococcus aureus.

Authors:  R H Deurenberg; C Vink; S Kalenic; A W Friedrich; C A Bruggeman; E E Stobberingh
Journal:  Clin Microbiol Infect       Date:  2007-03       Impact factor: 8.067

10.  Allelic variation in genes encoding Panton-Valentine leukocidin from community-associated Staphylococcus aureus.

Authors:  D J Wolter; F C Tenover; R V Goering
Journal:  Clin Microbiol Infect       Date:  2007-08       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.